{
  "docId": "019de076-2ada-7117-9358-036add78e997",
  "docSlug": "d07954bb4369650f4386921d5f3a9e2d",
  "documentTitle": "Dare Bioscience | Results Presentation Deck | 14 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 14,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Includes logos for Bayer and NIH/NICHD.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-2ada-7117-9358-036add78e997/6",
  "deckHref": "/decks/019de076-2ada-7117-9358-036add78e997",
  "deckJsonHref": "/decks/019de076-2ada-7117-9358-036add78e997.json",
  "deckAnchorHref": "/decks/019de076-2ada-7117-9358-036add78e997#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.14,
        "x": 0.22,
        "y": 0.26
      },
      "kind": "image",
      "text": "Bayer and NIH logos",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1dd34c2c-3570-4053-a7b3-e9c267bdf480",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.43,
        "x": 0.51,
        "y": 0.34
      },
      "kind": "list",
      "text": "Continued progress toward patient enrollment for the anticipated start of our pivotal Phase 3 study. Multi-center, single arm, non-comparative, pivotal Phase 3 contraceptive study. On track to start enrolling patients in this fourth quarter of 2023.* Based on our communications to date with the FDA, if successful, we believe only this single registration study will be required to support a premarket approval application submission with the FDA.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15d40d94-db9e-459a-b483-2f02e4cd7ca2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.43,
        "x": 0.06,
        "y": 0.42
      },
      "kind": "list",
      "text": "Potential first-in-category hormone-free contraception. Self-administered intravaginal drug/device. Designed to be an easy-to-use monthly option. Commercial license agreement with Bayer. Pivotal study collaboration with NICHD.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5a8d4c8-6837-4a7d-825c-f08644fd18b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.43,
        "x": 0.06,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "Ovaprene® Investigational Hormone-Free, Monthly Contraceptive Pivotal Phase 3 Study to Commence 2023*",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c75ac92-b0c9-429f-b3ba-6b1d31a91c18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.21,
        "x": 0.51,
        "y": 0.28
      },
      "kind": "title",
      "text": "Recent Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18b25aa6-53d3-44fa-9fbf-96274028404e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.16,
        "x": 0.42,
        "y": 0.03
      },
      "kind": "title",
      "text": "Ovaprene®",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e5c1c5e-8c5b-4623-ace8-5bfb41f1758a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.32,
        "x": 0.34,
        "y": 0.15
      },
      "kind": "title",
      "text": "Late-Stage Program",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b62770f3-84ce-487e-8b04-678ec59e563f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "ebc93eba-c6ef-4933-9beb-410075ff330e",
      "evidence": "list/bullet: Continued progress toward patient enrollment for the anticipated start of our pivotal Phase 3 study. Multi-center, single arm, non-comparative, pivotal Phase 3 contraceptive study.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 4,
      "beatId": "92f61315-0ec9-42c1-ab7f-82fcf870c4ba",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 4-7 outline Daré Bioscience's product portfolio and pipeline",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}